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Guidelines summarise and evaluate all currently available
evidence on a particular issue with the aim of assisting
physicians in selecting the best management strategy for an
individual patient suffering from a given condition. Since
August 2010, when ESC guidelines for the management of
atrial fibrillation (AF) were published, European regulatory
approvals of several new drugs were announced, reports from
major clinical trials of the novel oral anticoagulants revealed,
and one antiarrhythmic drug study was early discontinuated.
Therefore, an update of the ESC guidelines was prepared. It is
not intended as a comprehensive new guideline. This article
is the summary of an update to the 2010 ESC Guidelines.
The prevalence of (AF) in developed countries is now
estimated to be 1.5–2% of the general population. Many
episodes of AF are silent. Diagnosis of AF before the compli-
cations occur is important. Recent data collected in patients
with implanted devices reinforced the assumption that even
short episodes of silent AF convey an increased risk of stroke.
Therefore it is recommended that in patients aged 65 years or
over, screening for AF by pulse palpation, followed by record-
ing of an ECG to verify diagnosis, should be considered.2. Stroke and bleeding risk assessment
The term valvular AF is used to imply that AF is related to
rheumatic valvular disease (predominantly mitral stenosis)
or prosthetic heart valves. Stroke risk stratification proposed
in that guideline is more focused on the identification of
‘truly low-risk’ patients who do not need any antithrombotic
therapy, and more evidence on the use of novel oral antic-
oagulant drugs (NOACs; see below) as alternatives to dose-
adjusted vitamin K antagonist (VKA) therapy [e.g. warfarin,
international normalised ratio (INR) 2.0–3.0].
Given the availability of NOACs, the use of antiplatelet
therapy (such as aspirin–clopidogrel combination therapy, or
– less effectively – aspirin monotherapy) for stroke prevention
in AF should be limited to the few patients who refuse any
form of OAC. There is no evidence for the decrease in total or
cardiovascular mortality with aspirin (or antiplatelet drugs)
in the AF population. Patients with AF who have stroke risk
factor(s) Z1 are recommended to receive effective stroke
prevention therapy, which is essentially OAC with eitherwell-controlled VKA therapy [INR 2–3, with a high percentage
of time in the therapeutic range (TTR), for example, at least
70%] or one of the NOACs.
Whilst the CHADS2 [Congestive heart failure, Hypertension,
Age Z75, Diabetes, Stroke (doubled)] score is simple, most now
agree that it does not include many common stroke risk factors
and its limitations have been highlighted. For example, vascular
disease (not included in the CHADS2 score) is an independent
risk factor for stroke in AF and significantly improves the
predictive ability of CHADS2. Many patients classified as ‘low-
risk’ using CHADS2 (score¼0) have stroke rates 1.5%/year, and a
CHADS2 score of 0 does not reliably identify AF patients who are
‘truly low-risk’.
The 2010 ESC Guidelines on AF de-emphasised the use of
the artificial low-, moderate-, and high-risk strata and
recommended a risk factor-based approach defining ‘major’
and ‘clinically relevant non-major’ risk factors, which can be
expressed as an acronym, CHA2DS2-VASc (Congestive heart
failure/left ventricular dysfunction, Hypertension, Age Z75
[doubled], Diabetes, Stroke [doubled]—Vascular disease, Age
65–74, and Sex category [female]).
Antithrombotic therapy is not recommended in patients
with AF (irrespective of gender) who are ‘aged o65 and lone
AF (i.e. truly ‘low-risk’), as the latter have very low absolute
event rates.
The CHA2DS2-VASc score is inclusive of the most common
stroke risk factors in everyday clinical practice. Contrary to older,
conflicting (and weak) data, thyroid disease (or hyperthyroidism)
is not considered to be an independent stroke risk factor on
multivariable analysis. A history of ‘any heart failure’ per se is
not consistently defined as a risk factor, and the ‘C’ in CHA2DS2-
VASc refers to documented moderate-to-severe systolic dysfunc-
tion [i.e. heart failure with reduced ejection fraction (HF-REF)]
or patients with recent decompensated heart failure requiring
hospitalisation, irrespective of ejection fraction [i.e. both HF-REF
and heart failure with preserved ejection fraction (HF-PEF)].
Female gender independently increases the risk of stroke
overall, unless the criterion of ‘ageo65 and lone AF’ is clearly
fulfilled, whereby female gender does not independently
increase stroke risk. Stroke rates in patients with the criterion
of ‘ageo65 and lone AF’ are so low in both males and females
that antithrombotic therapy is not recommended. Thus, female
patients with gender alone as a single risk factor would not
need anticoagulation. CHA2DS2-VASc refines stroke risk assess-
ment in ‘low-risk’ AF patients after ablation.
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stroke, but are also at increased risk for death, coronary
events and serious bleeding. These patients have not been
adequately studied and have been excluded from clinical
trials, and their risk assessment is complex.
Decision-making for thromboprophylaxis needs to balance
the risk of stroke against the risk of major bleeding, especially
ICH, which is the most feared complication of anticoagula-
tion therapy and confers a high risk of death and disability.
The 2010 ESC Guidelines on AF recommended use of the
simple bleeding risk assessment score, HAS-BLED. The HAS-
BLED score highlights risk factors that can be actively man-
aged to reduce the bleeding risk. The HAS-BLED score has
been validated in several independent cohorts, and correlates
well with ICH risk. It is noteworthy that the ICH (and major
bleeding) rate in patients on aspirin, for a given HAS-BLED
score, was similar to that for those taking warfarin.
Thus, a formal bleeding risk assessment is recommended for
all patients with AF, and in patients with a HAS-BLED scoreZ3,
caution and regular review are appropriate, as well as efforts to
correct the potentially reversible risk factors for bleeding. The
HAS-BLED score per se should not be used to exclude patients
from OAC therapy but allows clinicians to make an informed
assessment of bleeding risk (rather than relying on guesswork)
and, importantly, makes them think of the correctable risk
factors for bleeding: for example, uncontrolled blood pressure,
concomitant use of aspirin/non-steroidal anti-inflammatory
drugs (NSAIDs), labile INRs, etc. Use of the CHA2DS2-VASc and
HAS-BLED scores to aid practical decision-making for thrombo-
prophylaxis in non-valvular AF has recently been reviewed.
In the net clinical benefit analysis-balancing ischaemic
stroke against intracranial bleeding-by Olesen et al. those
patients with a high HAS-BLED score had an even greater net
clinical benefit with warfarin, given that the higher-risk
individuals would have a much greater absolute reduction
in stroke risk with warfarin, which would outweigh the small
absolute increase in major bleeding events.
Additional evidence emphasises that stroke prevention
with a VKA is effective where the individual mean time in
therapeutic range (TTR) is good; for example 70%. Thus,
where a VKA is used, efforts to improve quality of INR control
are needed in order to achieve high TTRs.3. Novel oral anticoagulants
The NOACs for stroke prevention in AF fall into two classes: the
oral direct thrombin inhibitors (e.g. dabigatran) and oral direct
factor Xa inhibitors (e.g. rivaroxaban, apixaban, etc.). In contrast
to VKAs, which block the formation of multiple active vitamin
K-dependent coagulation factors (factors II, VII, IX, and X), these
drugs block the activity of one single step in coagulation.
Another oral factor Xa inhibitor with an ongoing, large phase
III trial is edoxaban; this will probably be reported in 2013.
3.1. Practical considerations
The NOACs so far tested in clinical trials have all shown
noninferiority compared with VKAs, with better safety, con-
sistently limiting the number of ICH. On this basis, thisguideline now recommends them as broadly preferable to
VKA in the vast majority of patients with non-valvular AF,
when used as studied in the clinical trials performed so far.
Since there is still limited experience with these agents, strict
adherence to approved indications and careful post-
marketing surveillance are strongly recommended.
In the absence of head-to-head trials, it is inappropriate to
be definitive on which of the NOACs is best, given the
heterogeneity of the different trials. Indirect comparison
analyses do not suggest profound differences in efficacy
endpoints between the NOACs, but major bleeding appears
lower with dabigatran 110 mg b.i.d. and apixaban. Patient
characteristics, drug tolerability, and cost may be important
considerations. Some costeffectiveness data for dabigatran
have been published in various healthcare settings, and
dabigatran appears to be cost-effective for most patients,
except in those with very well-controlled INRs. None of the
novel OACs has a specific antidote.
The net clinical benefit of VKAs, balancing ischaemic
stroke against ICH in patients with non-valvular AF, has been
modelled on to stroke and bleeding rates from the Danish
nationwide cohort study for dabigatran, rivaroxaban, and
apixaban, on the basis of recent clinical trial outcome data
for these NOACs. At a CHA2DS2-VASc score of 1, apixaban and
both doses of dabigatran (110 mg b.i.d. and 150 mg b.i.d.) had
a positive net clinical benefit while, in patients with
CHA2DS2-VASc score Z2, all three NOACs were superior to
warfarin, with a positive net clinical benefit, irrespective of
bleeding risk. When switching from a VKA to a NOAC, the INR
should be allowed to fall to about 2.0 before starting the
NOAC, all of which have rapid onset of anticoagulation effect.
When changing from a NOAC to a VKA, overlap with VKA for
2–3 days is necessary, as VKAs would take a few days to
achieve therapeutic anticoagulation.
Compliance and adherence to treatment is crucial, especially
since these drugs have a relatively short half-life, such that
patients would be left without any anticoagulation protection if
more than one dose were missed. Renal function should be
assessed annually in patients with normal (CrCl Z80mL/min)
or mild (CrCl 50–79 mL/min) renal impairment, and perhaps
2–3 times per year in patients with moderate (i.e. creatinine
clearance 30–49 mL/min) renal impairment. Dabigatran may
also cause dyspepsia, which may perhaps be ameliorated by
taking the drug with food or the use of a proton pump
inhibitor.
The NOACs do not require dose adjustment on the basis of
a specific coagulation test (in contrast to the INR for VKAs).
There are non-specific coagulation tests that can be used to
check for the presence of an anticoagulation effect (rather
than anticoagulation intensity per se). These should not be
used for dose adjustment. For dabigatran, the ecarin clotting
time and thrombin clotting time are useful tests, and directly
reflect thrombin inhibition however, an activated partial
thromboplastin time (aPTT) can also be used (especially in
an emergency setting), although the correlation is not linear,
particularly at higher concentrations. Rivaroxaban prolongs
the prothrombin time (PT) and this might be used as a rough
estimate of an anticoagulation effect. A better estimate for an
anticoagulant effect for the oral Factor Xa inhibitors is an
anti-Xa assay.
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agement of bleeding is thus largely supportive, given that
these drugs have a relatively short (5–17 h) half-life. One
small study suggested normalisation of coagulation tests
with nonactivated prothrombin complex concentrate
COFACT (Sanquin Blood Supply, Amsterdam, the Nether-
lands) administered to healthy and relatively young indivi-
duals taking rivaroxaban, but no effect was seen with
dabigatran. Another study found that low-dose FEIBA (Baxter
AG, Vienna, Austria) reversed the anticoagulant activity of
rivaroxaban and dabigatran.
Perioperative management is another important considera-
tion. Given the rapid onset and offset of action of dabigatran
etexilate, no bridging therapy with low molecular weight
heparin (LMWH) is required for the majority of interventions.
Following surgery, NOACs can be restarted as soon as effec-
tive haemostasis has been achieved.
The available data suggest that elective cardioversion can
be safely performed on dabigatran, with the requirement for
3 weeks of therapeutic anticoagulation pre-cardioversion and
4 weeks post-cardioversion. Drug compliance is crucial for
the anticoagulation period peri-cardioversion as, unlike the
INR for VKAs, there is no easy means to assess therapeutic
anticoagulation. No published data on cardioversion with
rivaroxaban or apixaban are yet available.
Data from limited case series suggest that appropriate
post-ablation management with dabigatran is associated
with a low risk of embolic or bleeding complications,
although brief interruption of dabigatran use is associated
with more thromboembolic and bleeding complications.
Patients taking the NOACsmay present with an acute coronary
syndrome (ACS) and/or undergo percutaneous coronary inter-
vention (PCI). Concomitant use of antiplatelet therapy with the
NOACs significantly increases bleeding risk, as is the case with
combining any OAC with antiplatelet therapy.
The only trial where clopidogrel use was not contraindi-
cated was RE-LY, so the data on triple therapy with a NOAC(when given at stroke prevention doses in AF patients) are
limited. Patients with AF and stable vascular disease (i.e. no
acute events or revascularization for 412 month whether
coronary or peripheral artery disease) can be managed with
OAC alone, whether as adjusted dose VKA therapy, or prob-
ably a NOAC. In such stable patients, there is no need for
concomitant aspirin, which could increase the risk of serious
haemorrhage, including intracranial haemorrhage.
Patients taking the NOACs may also present with an acute
ischaemic stroke. If the aPTT is prolonged in a patient taking
dabigatran (or the PTwith rivaroxaban), it should be assumed
that the patient is anticoagulated, and thrombolysis should
not be administered. Given that dabigatran 150 mg b.i.d. did
result in a significant reduction in both ischaemic and
haemorrhagic stroke, should the acute ischaemic stroke
occur whilst the patient is taking rivaroxaban or apixaban
(neither of which significantly reduced ischaemic stroke,
compared with warfarin, in their respective trials), the clin-
ician may consider the use of dabigatran 150 mg b.i.d.
instead. Algorithms illustrating the choice of antithrombotic
therapy and the management of bleeding in patients on
NOACs in patients with AF are shown in Figs. 1 and 2.
Although NOACs may be preferred on the basis of clinical
trial data clinicians should remain aware that clinical experi-
ence with these agents is still limited and that care, vigilance
and further information on their effectiveness in clinical
practice are needed.
Key points The efficacy of stroke prevention with aspirin is weak,
with a potential for harm, since the risk of major bleeding
(and ICH) with aspirin is not significantly different to that
of OAC, especially in the elderly. The use of antiplatelet therapy (as aspirin–clopidogrel
combination therapy or – less effectively – aspirin mono-
therapy for those who cannot tolerate aspirin—clopidogrel
Check haemodynamic status, basic coagulation tests
to assess anticoagulation effect (e.g. aPTT for 
dabigatran, PT or anti Xa activity for rivaroxaban),
renal function, etc.
Minor
Moderate–severe
Very severe
Delay next dose or
discontinue treatment
Symptomatic/supportive
treatment
Mechanical compression
Fluid replacement
Blood transfusion
Oral charcoal if recently
ingesteda
Consider
rFVIIa or PCC
Charcoal filtrationa/
haemodialysisa
aPTT = activated partial thromboplastin time; NOAC = novel oral anticoagulant;
PCC = prothrombin complex concentrate; PT = prothrombin time;
rFVIIa = activated recombinant factor VII.
ªWith dabigatran.
Patient on NOAC presenting with bleeding
Fig. 2 – Management of bleeding in patients taking novel
oral anticoagulants.
Valvular AFa
<65 years and lone AF (including females)
Oral anticoagulant therapy
Assess bleeding risk
(HAS-BLED score)
Consider patient values
and preferences
NOAC VKANo antithrombotic
therapy
Antiplatelet therapy with aspirin plus clopidogrel, or—less effectively—aspirin
only, should be considered in patients who refuse any OAC, or cannot tolerate
anticoagulants for reasons unrelated to bleeding. If there are contraindications to
OAC or antiplatelet therapy, left atrial appendage occlusion, closure or excision
may be considered.
Colour: CHA2DS2-VASc; green = 0, blue = 1, red ≥2.
Line: solid = best option; dashed = alternative option.
AF = atrial fibrillation; CHA2DS2-VASc = see text; HAS-BLED = see text;
NOAC = novel oral anticoagulant; OAC = oral anticoagulant;
VKA = vitamin K antagonist.
ªIncludes rheumatic valvular disease and prosthetic valves.
Assess risk of stroke
(CHA2DS2-VASc score)
No
No (i.e., non-valvular AF)
0 1 2
Yes
Yes
Atrial fibrillation
Fig. 1 – Choice of anticoagulant.
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be limited to the few patients who refuse any form of OAC. The CHA2DS2-VASc score is better at identifying ‘truly low-
risk’ patients with AF and is as good as – and possibly
better than – scores such as CHADS2 in identifying
patients who develop stroke and thromboembolism. The HAS-BLED score allows clinicians to make an
informed assessment of bleeding risk and, importantly,
makes them think of the correctable risk factors for
bleeding. In patients with a HAS-BLED score Z3, caution
and regular review are recommended, as well as efforts to
correct the potentially reversible risk factors for bleeding.
A high HAS-BLED score per se should not be used to
exclude patients from OAC therapy. The NOACs offer better efficacy, safety, and convenience
compared with OAC with VKAs. Thus, where an OAC is
recommended, one of the NOACs – either a direct thrombin
inhibitor (dabigatran) or an oral factor Xa inhibitor (e.g.
rivaroxaban, apixaban) – should be considered instead of
adjusted-dose VKA (INR 2–3) for most patients with AF. There is insufficient evidence to recommend one NOAC
over another, although some patient characteristics, drug
compliance and tolerability, and cost may be important
considerations in the choice of agent.4. Left atrial appendage closure
The left atrial appendage (LAA) is considered the main (but
not the only) site of thrombus formation inducing ischaemic
stroke in patients suffering from AF. Trans-oesophageal
echocardiography detects most thrombi in the LAA and low
stroke rates are reported in patients in whom the LAA has
been surgically removed. Surgical exciton or stapling of the
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open heart surgery. More recently, minimally invasive epicar-
dial techniques and interventional trans-septal or also epi-
cardial techniques have been developed for occlusion of the
LAA orifice to reduce the stroke risk.
Although clinically applied for decades, there is no con-
clusive evidence that surgical LAA excision or occlusion
reduces stroke risk in AF patients. There are no large,
controlled trials with systematic follow-up. Furthermore,
some data to suggest that not all strokes in AF patients are
cardio-embolic or due to AF, and the
LAA is probably not the only left atrial region where
thrombi can potentially originate. This suggests that there
may be a need for antithrombotic therapy in AF patients,
even after removal or closure of the LAA.
Data from retrospective or observational studies in different
patient populations have shown inconsistent results of surgical
LAA excision or occlusion. In addition, no conclusive data are
available on the best surgical technique for performing LAA
closure. Risks of surgical LAA excision include major bleeding
and incomplete LAA occlusion with residual stroke risk. Non-
randomized observational studies, involving relatively small
numbers of patients, have shown the feasibility of percutaneous
LAA occlusion. Currently, two self-expanding devices, the
WATCHMAN (Boston Scientific, Natick, MA, USA) and the
Amplatzer Cardiac Plug (St. Jude Medical, St. Paul, MN, USA),
are available for clinical use in Europe,
The WATCHMAN LAA system for embolic PROTECTion in
patients with Atrial Fibrillation (PROTECT AF) trial randomized
707 eligible patients either to percutaneous closure of the LAA,
using the WATCHMAN device, or to OAC (INR range 2–3). The
primary efficacy event rate (composite endpoint of stroke,
cardiovascular death, and systemic embolism) in the LAA occlu-
sion group was non-inferior to patients treated with OAC. There
was a high rate of adverse events in the intervention group,
mainly due to peri-procedural complications. Many of the
adverse events in the intervention group occurred early in the
trial, indicative of an learning curve. A second randomized trial,
PREVAIL is currently enroling patients. In a feasibility and safety
study, LAA occlusion with the Amplatzer Cardiac Plug was
attempted in 137 of 143 patients, and was successfully per-
formed in 96% of patients. A randomized prospective study with
the device is currently under way (Amplatzer Cardiac Plug Trial).
Although the concept of LAA closure seems reasonable, the
evidence of efficacy and safety is currently insufficient to
recommend these approaches for any patients other than
those in whom long-term OAC is ineffective or contraindi-
cated. At present, LAA closure is not indicated simply as an
alternative to OAC therapy to reduce stroke risk. If the
efficiency of LAA closure will be conclusively shown in the
future, it could potentially replace long-term OAC. However,
other studies comparing interventional/percutaneous/surgi-
cal LAA closure with NOAC drugs will be needed.5. Cardioversion with pharmacological agents
Since the last ESC guidelines, a new intravenous antiarrhythmic
agent, vernakalant, has been approved for pharmacological
cardioversion.Vernakalant acts preferentially in the atria by blocking
several ion channels, resulting in prolongation of atrial
refractoriness and rate-dependent slowing of atrial conduc-
tion, but has little impact on currents involved in ventricular
depolarisation. Vernakalant has rapid onset of action and
mean elimination half-life of 3–5 h.
Key points: Vernakalant is effective in cardioversion of patients with
AFr7 days orr3 days after cardiac surgery and provides a
rapid antiarrhythmic effect with approximately 50% of
patients converting within 90 min after the start of treat-
ment and median time to conversion of 8–14 min. Vernakalant is administered as a 10 min infusion of 3 mg/
kg and, if AF persists after 15 min, a second infusion of
2 mg/kg can be given. Vernakalant has a satisfactory safety profile in patients with
minimal to moderate heart disease, including ischaemic
heart disease, but should be used with caution in haemody-
namically stable patients with NYHA class I and II heart
failure, because of increased risk of hypotension and non-
sustained ventricular arrhythmias in these patients. Vernakalant is contraindicated in patients with hypoten-
sion o100 mmHg, recent acute coronary syndrome (o30
days), NYHA class III and IV heart failure, severe aortic
stenosis, and QT interval prolongation (QT4440 ms).
The integration of vernakalant into the general schema for
pharmacological and electrical cardioversion is shown in Fig. 3.6. Oral antiarrhythmic drug therapy
6.1. Upstream therapy
All of the recent placebo-controlled, double blind trials
with angiotensin-receptors blockers (ARBs) and the majority
of trials with polyunsaturated fatty acids failed to
show convincing results. There is very little reason to con-
sider the use of such therapy for the prevention of AF in
patients with little or no underlying heart disease. It
may be justified to co-prescribe an ARB or an angiotensin-
converting enzyme inhibitor with an antiarrhythmic
drug to increase the likelihood of maintaining sinus rhythm
after cardioversion.6.2. Principles of antiarrhythmic drug therapy
Oral antiarrhythmic drug therapy can be considered for the
treatment of recurrent AF. It is important to emphasise that
antiarrhythmic drug therapy should only be offered to control
resistant symptoms due to recurrent AF and that a safety-
first principle should prevail.
Antiarrhythmic drug therapy for AF has generally been
given as long-term therapy. The short-term antiarrhythmic
drug therapy (4 weeks) after cardioversion should not be the
default type of treatment and should not be considered with
amiodarone, but may be useful in patients who are either at
Haemodynamic instability
Severe None
Patient/physician choice
Structural heart disease
Moderate
Intravenous
amiodarone
aIbutilide should not be given when significant left ventricular hypertrophy
(≥1.4 cm) is present.
bVernakalant should not be given in moderate or severe heart failure, aortic
stenosis, acute coronary syndrome or hypotension. Caution in mild
heart failure.
c'Pill-in-the-pocket' technique – preliminary assessment in a medically safe
environment and then used by the patient in the ambulatory setting.
Electrical
cardioversion
Intravenous
flecainide
ibutilide
propafenone
vernakalant
Pill-in-the-pocket
(high dose oral)c
flecainide
propafenone
Intravenous
ibutilidea
vernakalantb
Intravenous
amiodarone
Intravenous
amiodarone
ElectiveEmergency
oNseY
Electrical
Pharmacological
Recent-onset AF
Fig. 3 – Indications for electrical and pharmacological cardioversion, and choice of antiarrhythmic drugs for pharmacological
cardioversion in patients with recent-onset AF.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 3 4 1 – e 3 5 1e348high risk for drug-induced adverse effects or for patients with
infrequent recurrences of AF.
6.3. Update on dronedarone
As a consequence of the PALLAS (Permanent Atrial fibrilLA-
tion outcome Study) trial (prematurely stopped due to an
increase in cardiovascular events including cardiovascular
mortality in the dronedarone arm), patients with permanent
AF should not be treated with dronedarone, particularly those
with a significant cardiovascular disease burden. The drug
can still be used in patients with paroxysmal or persistent AF
after cardioversion. The drug is contraindicated in patients
with unstable haemodynamic conditions, with a history of
(or current) heart failure or left ventricular dysfunction (EMA
update on dronedarone). Use of dronedarone as an antiar-
rhythmic agent in patients with recurrent AF and less severe
heart failure (NYHA class I–II) is not appropriate unless there
is no suitable alternative.
There was a signal in the PALLAS trial that dronedarone was
associated with increased sudden mortality in patients on
concomitant digoxin therapy; hence the combined use of these
two drugs is discouraged. Dronedarone has also been associated
with severe hepatotoxicity in a few instances. Hence, monitoring
of liver function tests is advisable in patients on long termdronedarone treatment. Since dronedarone is a P-glycoprotein
inhibitor, it increases plasma concentrations of dabigatran;
therefore concomitant use of the two drugs has to be avoided.
Key points: Rhythm-control therapy is indicated to relieve symptoms
associated with AF. Antiarrhythmic drugs should not be used for rate control
in patients with permanent AF, unless appropriate rate
control agents fail. In selected patients, limiting antiarrhythmic drug therapy
to 4 weeks after cardioversion may help to improve safety. The choice of an antiarrhythmic drug should be driven by
perceived safety of the drug, this is more important than
perceived efficacy. Dronedarone is appropriate for maintaining sinus rhythm
in patients with paroxysmal or persistent AF. Dronedarone should not be given to patients with moderate
or severe heart failure, and should be avoided in patientswith
less-severe heart failure, if appropriate alternatives exist.The current choice of antiarrhythmic drugs related to
underlying pathophysiology is illustrated in Fig. 4.
Minimal or no structural 
heart disease
dronedarone/flecainide/ 
propafenone/sotalol
amiodarone amiodarone
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; HHD = hypertensive heart
disease; CHD = coronary heart disease; HF = heart failure;
LVH = left ventricular hypertrophy, NYHA = New York Heart Association. Antiarrhythmic agents are listed in
alphabetical order within each treatment box.
amiodarone
Significant structural heart disease
Treatment of underlying condition and prevention
of remodelling – ACEI/ARB/statin
HHD
sotalol
dronedarone dronedarone
No LVH LVH
CHD HF
Fig. 4 – Choice of antiarrhythmic drug according to underlying pathology.
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7.1. New evidence for catheter ablation
Since the publication of the ESC AF Guidelines in 2010,
several new sets of data have become available.
These data further support the 2010 recommendation that it is
reasonable to recommend catheter ablation as first-line therapy
for AF rhythm control in selected patients, i.e. those with
paroxysmal
AF preferring interventional treatment with a low risk
profile. Other reports also report that catheter ablation is
more effective than antiarrhythmic drug therapy for the
maintenance of sinus rhythm in patients with AF, mostly in
patients without marked structural heart disease. While
catheter ablation is more effective than antiarrhythmic
drugs, the number of AF recurrences during the long-term
follow-up seems to be significant. The most important pre-
dictor for such late recurrence appears to be early recurrence
of AF after the ablation procedure. A low rate of recurrences,
which may be due to progression of atrial damage, continues
to add up to relevant, long-term recurrence rates.
Catheter ablation of AF conveys a relevant risk of major
complications. This is illustrated by the recent publication of
the pilot survey of AF ablation within the EURObservational
Research Programme, which included also five Czech centers.In this survey, which reported the outcome of more than 1000
ablation procedures carried out in high-volume centres through-
out Europe, acute severe complication rates were 0.6% for stroke,
1.3% for tamponade, 1.3% for peripheral vascular complications,
and around 2% for pericarditis. In a very recent medical database
analysis in 4156 patients who underwent their initial ablation
between 2005 and 2008, the complication rate was 5% and the
rate of all-cause hospitalisation in the first year after catheter
ablation was 38.5%. Furthermore, some reports suggest that
silent cerebral infarctions, detectable by cerebral magnetic reso-
nance imaging, may be induced by catheter ablation procedures.
The clinical significance of this silent cerebral infarction is
unclear, but these risks need to be carefully considered, when
selecting an ablation tool or technology.
7.2. Catheter ablation in patients with heart failure
The recommendations for antiarrhythmic drug therapy leave
amiodarone as the only available antiarrhythmic agent in
patients with severe heart failure. In patients who suffer from
symptomatic AF recurrences on amiodarone therapy, catheter
ablation remains as the sole choice for escalated rhythm control
therapy.
The likelihood of maintaining sinus rhythm after ablation
is lower and the procedure-related risks may be higher in
heart failure patients.
amiodarone
Patient choice
a
b
Patient choice
Patient choice
Catheter
ablation
dronedarone,
flecainide,
propafenone,
sotalol
PersistentParoxysmal Yes No
Yes
No
No or minimal structural heart disease
amiodarone
HF
Catheter ablationb
AF = atrial fibrillation; HF = heart failure. aUsually pulmonary vein isolation is appropriate. bMore extensive left atrial ablation may be needed.
cCaution with coronary heart disease. dNot recommended with left ventricular hypertrophy. Heart failure due to AF = tachycardiomyopathy.
dronedaronec
/sotalold
Relevant structural heart disease
Due to AF
Fig. 5 – Antiarrhythmic drugs and/or left atrial ablation for rhythm control in AF.
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There is consensus that OAC is helpful to prevent throm-
boembolic complications around ablation procedures.
Several reports suggest that catheter ablation of AF may be
performed with fewer complications when OAC therapy is
continued (usually VKA). These reports also conclude that
continuous OAC is safe during ablation. At present, for
patients on OAC with VKA, we therefore recommend under-
taking catheter ablation of AF on continuous anticoagulation.
Anticoagulant therapy should be kept at low therapeutic
levels (such as an INR of 2 to 2.5) throughout ablation.
Experience with NOACs is limited. Initial reports suggest
that the stroke risk may be slightly increased.
Exact relative risk of uninterrupted OAC with NOACs peri-
ablation is not known. For patients taken off OAC before the
ablation procedure, initiation of anticoagulation with NOAC
shortly after the ablation procedure seems to be reasonable.7.4. Safety first
Improving safety of catheter ablation should be a primary
goal in the further development of this therapy.
However, pathophysiological considerations suggest that
rhythm control therapy may be best performed early after the
initial diagnosis, as this time period may provide a ‘window
of opportunity’ for effective rhythm control therapy.7.5. New considerations for AF catheter ablation
Considering the results of randomized studies on catheter
ablation of AF vs. antiarrhythmic drug therapy and recent
publications from randomized and non-randomized trials, it is
reasonable to upgrade this recommendation to class I. For
patients with highly symptomatic paroxysmal AF with a low-
risk profile for catheter ablation, primary catheter ablation
should be considered (Fig. 5). These recommendations are
restricted to: (i) highly experienced centres/investigators; (ii)
appropriate patient selection; (iii) careful evaluation of treatment
alternatives and (iv) patient preference. For patients with drug-
refractory persistent and long-standing persistent AF, there is no
change in recommendations. Currently there is no evidence to
recommend catheter ablation of AF in asymptomatic patients.
Key points Catheter ablation is recommended as an alternative to
antiarrhythmic drug therapy for patients with sympto-
matic recurrent paroxysmal AF on antiarrhythmic drug
therapy, provided the procedure is performed by an
experienced operator. Continuation of oral VKA therapy can be considered
throughout the ablation procedure but robust data for
NOACs are lacking. In selected patients with paroxysmal AF and no structural
heart disease left atrial ablation is reasonable as first-line
therapy.
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